Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Anna Latos-Bielenska is active.

Publication


Featured researches published by Anna Latos-Bielenska.


American Journal of Human Genetics | 1999

Splicing Mutations of 54-bp Exons in the COL11A1 Gene Cause Marshall Syndrome, but Other Mutations Cause Overlapping Marshall/Stickler Phenotypes

Susanna Annunen; Jarmo Körkkö; Malwina Czarny; Matthew L. Warman; Han G. Brunner; Helena Kääriäinen; John B. Mulliken; Lisbeth Tranebjærg; David G. Brooks; Gerald F. Cox; Johan R.M. Cruysberg; Mary Curtis; Sandra L. H. Davenport; Christopher A. Friedrich; Ilkka Kaitila; Maciej R. Krawczynski; Anna Latos-Bielenska; Shitzuo Mukai; Björn Olsen; Nancy W. Shinno; Mirja Somer; Miikka Vikkula; Joël Zlotogora; Darwin J. Prockop; Leena Ala-Kokko

Stickler and Marshall syndromes are dominantly inherited chondrodysplasias characterized by midfacial hypoplasia, high myopia, and sensorineural-hearing deficit. Since the characteristics of these syndromes overlap, it has been argued whether they are distinct entities or different manifestations of a single syndrome. Several mutations causing Stickler syndrome have been found in the COL2A1 gene, and one mutation causing Stickler syndrome and one causing Marshall syndrome have been detected in the COL11A1 gene. We characterize here the genomic structure of the COL11A1 gene. Screening of patients with Stickler, Stickler-like, or Marshall syndrome pointed to 23 novel mutations. Genotypic-phenotypic comparison revealed an association between the Marshall syndrome phenotype and splicing mutations of 54-bp exons in the C-terminal region of the COL11A1 gene. Null-allele mutations in the COL2A1 gene led to a typical phenotype of Stickler syndrome. Some patients, however, presented with phenotypes of both Marshall and Stickler syndromes.


European Journal of Human Genetics | 2013

Twenty-year trends in the prevalence of Down syndrome and other trisomies in Europe: impact of maternal age and prenatal screening

Maria Loane; Joan K. Morris; Marie-Claude Addor; Larraitz Arriola; Judith L. S. Budd; Bérénice Doray; Ester Garne; Miriam Gatt; Martin Haeusler; Babak Khoshnood; Kari Klungsøyr Melve; Anna Latos-Bielenska; Bob McDonnell; Carmel Mullaney; Mary O'Mahony; Annette Queißer-Wahrendorf; Judith Rankin; Anke Rissmann; Catherine Rounding; Joaquin Salvador; David Tucker; Diana Wellesley; Lyubov Yevtushok; Helen Dolk

This study examines trends and geographical differences in total and live birth prevalence of trisomies 21, 18 and 13 with regard to increasing maternal age and prenatal diagnosis in Europe. Twenty-one population-based EUROCAT registries covering 6.1 million births between 1990 and 2009 participated. Trisomy cases included live births, fetal deaths from 20 weeks gestational age and terminations of pregnancy for fetal anomaly. We present correction to 20 weeks gestational age (ie, correcting early terminations for the probability of fetal survival to 20 weeks) to allow for artefactual screening-related differences in total prevalence. Poisson regression was used. The proportion of births in the population to mothers aged 35+ years in the participating registries increased from 13% in 1990 to 19% in 2009. Total prevalence per 10 000 births was 22.0 (95% CI 21.7–22.4) for trisomy 21, 5.0 (95% CI 4.8–5.1) for trisomy 18 and 2.0 (95% CI 1.9–2.2) for trisomy 13; live birth prevalence was 11.2 (95% CI 10.9–11.5) for trisomy 21, 1.04 (95% CI 0.96–1.12) for trisomy 18 and 0.48 (95% CI 0.43–0.54) for trisomy 13. There was an increase in total and total corrected prevalence of all three trisomies over time, mainly explained by increasing maternal age. Live birth prevalence remained stable over time. For trisomy 21, there was a three-fold variation in live birth prevalence between countries. The rise in maternal age has led to an increase in the number of trisomy-affected pregnancies in Europe. Live birth prevalence has remained stable overall. Differences in prenatal screening and termination between countries lead to wide variation in live birth prevalence.


American Journal of Human Genetics | 2001

A Mutation in COL9A1 Causes Multiple Epiphyseal Dysplasia: Further Evidence for Locus Heterogeneity

Malwina Czarny-Ratajczak; Jaana Lohiniva; Piotr Rogala; K. Kozlowski; Merja Perälä; Liisa Carter; Tim D. Spector; Lukasz Kolodziej; Ulpu Seppänen; Renata Glazar; Jan Królewski; Anna Latos-Bielenska; Leena Ala-Kokko

Multiple epiphyseal dysplasia (MED) is an autosomal dominantly inherited chondrodysplasia. It is clinically highly heterogeneous, partially because of its complex genetic background. Mutations in four genes, COL9A2, COL9A3, COMP, and MATR3, all coding for cartilage extracellular matrix components (i.e., the alpha2 and alpha 3 chains of collagen IX, cartilage oligomeric matrix protein, and matrilin-3), have been identified in this disease so far, but no mutations have yet been reported in the third collagen IX gene, COL9A1, which codes for the alpha1(IX) chain. MED with apparently recessive inheritance has been reported in some families. A homozygous R279W mutation was recently found in the diastrophic dysplasia sulfate transporter gene, DTDST, in a patient with MED who had a club foot and double-layered patella. The series consisted of 41 probands with MED, 16 of whom were familial and on 4 of whom linkage analyses were performed. Recombination was observed between COL9A1, COL9A2, COL9A3, and COMP and the MED phenotype in two of the families, and between COL9A2, COL9A3, and COMP and the phenotype in the other two families. Screening of COL9A1 for mutations in the two probands from the families in which this gene was not involved in the recombinations failed to identify any disease-causing mutations. The remaining 37 probands were screened for mutations in all three collagen IX genes and in the COMP gene. The probands with talipes deformities or multipartite patella were also screened for the R279W mutation in DTDST. The analysis resulted in identification of three mutations in COMP and one in COL9A1, but none in the other two collagen IX genes. Two of the probands with a multipartite patella had the homozygous DTDST mutation. The results show that mutations in COL9A1 can cause MED, but they also suggest that mutations in COL9A1, COL9A2, COL9A3, COMP, and DTDST are not the major causes of MED and that there exists at least one additional locus.


Human Genetics | 2006

A novel X-linked recessive mental retardation syndrome comprising macrocephaly and ciliary dysfunction is allelic to oral–facial–digital type I syndrome

B Budny; Wei Chen; Heymut Omran; Manfred Fliegauf; Andreas Tzschach; Marzena Wisniewska; Lars R. Jensen; Martine Raynaud; Sarah A. Shoichet; Magda Badura; Steffen Lenzner; Anna Latos-Bielenska; Hans-Hilger Ropers

We report on a large family in which a novel X-linked recessive mental retardation (XLMR) syndrome comprising macrocephaly and ciliary dysfunction co-segregates with a frameshift mutation in the OFD1 gene. Mutations of OFD1 have been associated with oral–facial–digital type 1 syndrome (OFD1S) that is characterized by X-chromosomal dominant inheritance and lethality in males. In contrast, the carrier females of our family were clinically inconspicuous, and the affected males suffered from severe mental retardation, recurrent respiratory tract infections and macrocephaly. All but one of the affected males died from respiratory problems in infancy; and impaired ciliary motility was confirmed in the index patient by high-speed video microscopy examination of nasal epithelium. This family broadens the phenotypic spectrum of OFD1 mutations in an unexpected way and sheds light on the complexity of the underlying disease mechanisms.


American Journal of Human Genetics | 2010

Cranioectodermal Dysplasia, Sensenbrenner Syndrome, Is a Ciliopathy Caused by Mutations in the IFT122 Gene

Joanna Walczak-Sztulpa; Jonathan T. Eggenschwiler; Daniel P.S. Osborn; Desmond Brown; Francesco Emma; Claus Klingenberg; Raoul C. M. Hennekam; G. Torre; Masoud Garshasbi; Andreas Tzschach; Małgorzata Szczepańska; Marian Krawczyński; Jacek Zachwieja; Danuta Zwolińska; Philip L. Beales; Hans-Hilger Ropers; Anna Latos-Bielenska; Andreas W. Kuss

Cranioectodermal dysplasia (CED) is a disorder characterized by craniofacial, skeletal, and ectodermal abnormalities. Most cases reported to date are sporadic, but a few familial cases support an autosomal-recessive inheritance pattern. Aiming at the elucidation of the genetic basis of CED, we collected 13 patients with CED symptoms from 12 independent families. In one family with consanguineous parents two siblings were affected, permitting linkage analysis and homozygosity mapping. This revealed a single region of homozygosity with a significant LOD score (3.57) on chromosome 3q21-3q24. By sequencing candidate genes from this interval we found a homozygous missense mutation in the IFT122 (WDR10) gene that cosegregated with the disease. Examination of IFT122 in our patient cohort revealed one additional homozygous missense change in the patient from a second consanguineous family. In addition, we found compound heterozygosity for a donor splice-site change and a missense change in one sporadic patient. All mutations were absent in 340 control chromosomes. Because IFT122 plays an important role in the assembly and maintenance of eukaryotic cilia, we investigated patient fibroblasts and found significantly reduced frequency and length of primary cilia as compared to controls. Furthermore, we transiently knocked down ift122 in zebrafish embryos and observed the typical phenotype found in other models of ciliopathies. Because not all of our patients harbored mutations in IFT122, CED seems to be genetically heterogeneous. Still, by identifying CED as a ciliary disorder, our study suggests that the causative mutations in the unresolved cases most likely affect primary cilia function too.


American Journal of Human Genetics | 2012

Copy-Number Disorders Are a Common Cause of Congenital Kidney Malformations

Simone Sanna-Cherchi; Krzysztof Kiryluk; Katelyn E. Burgess; Monica Bodria; Matthew Sampson; Dexter Hadley; Shannon N. Nees; Miguel Verbitsky; Brittany J. Perry; Roel Sterken; Vladimir J. Lozanovski; Anna Materna-Kiryluk; Cristina Barlassina; Akshata Kini; Valentina Corbani; Alba Carrea; Danio Somenzi; Corrado Murtas; Nadica Ristoska-Bojkovska; Claudia Izzi; Beatrice Bianco; Marcin Zaniew; Hana Flögelová; Patricia L. Weng; Nilgun Kacak; Stefania Giberti; Maddalena Gigante; Adela Arapović; Kristina Drnasin; Gianluca Caridi

We examined the burden of large, rare, copy-number variants (CNVs) in 192 individuals with renal hypodysplasia (RHD) and replicated findings in 330 RHD cases from two independent cohorts. CNV distribution was significantly skewed toward larger gene-disrupting events in RHD cases compared to 4,733 ethnicity-matched controls (p = 4.8 × 10(-11)). This excess was attributable to known and novel (i.e., not present in any database or in the literature) genomic disorders. All together, 55/522 (10.5%) RHD cases harbored 34 distinct known genomic disorders, which were detected in only 0.2% of 13,839 population controls (p = 1.2 × 10(-58)). Another 32 (6.1%) RHD cases harbored large gene-disrupting CNVs that were absent from or extremely rare in the 13,839 population controls, identifying 38 potential novel or rare genomic disorders for this trait. Deletions at the HNF1B locus and the DiGeorge/velocardiofacial locus were most frequent. However, the majority of disorders were detected in a single individual. Genomic disorders were detected in 22.5% of individuals with multiple malformations and 14.5% of individuals with isolated urinary-tract defects; 14 individuals harbored two or more diagnostic or rare CNVs. Strikingly, the majority of the known CNV disorders detected in the RHD cohort have previous associations with developmental delay or neuropsychiatric diseases. Up to 16.6% of individuals with kidney malformations had a molecular diagnosis attributable to a copy-number disorder, suggesting kidney malformations as a sentinel manifestation of pathogenic genomic imbalances. A search for pathogenic CNVs should be considered in this population for the diagnosis of their specific genomic disorders and for the evaluation of the potential for developmental delay.


Birth Defects Research Part A-clinical and Molecular Teratology | 2011

Paper 6: EUROCAT member registries: organization and activities

Ruth Greenlees; Amanda J. Neville; Marie-Claude Addor; Emmanuelle Amar; Larraitz Arriola; Marian K. Bakker; Ingeborg Barišić; Patricia A. Boyd; Elisa Calzolari; Bérénice Doray; Elizabeth S. Draper; Stein Emil Vollset; Ester Garne; Miriam Gatt; Martin Haeusler; Karin Källén; Babak Khoshnood; Anna Latos-Bielenska; M.L. Martínez-Frías; Anna Materna-Kiryluk; Carlos Matias Dias; Bob McDonnell; Carmel Mullaney; Vera Nelen; Mary O'Mahony; Anna Pierini; Annette Queisser-Luft; Hanitra Randrianaivo-Ranjatoelina; Judith Rankin; Anke Rissmann

BACKGROUND EUROCAT is a network of population-based congenital anomaly registries providing standardized epidemiologic information on congenital anomalies in Europe. There are three types of EUROCAT membership: full, associate, or affiliate. Full member registries send individual records of all congenital anomalies covered by their region. Associate members transmit aggregate case counts for each EUROCAT anomaly subgroup by year and by type of birth. This article describes the organization and activities of each of the current 29 full member and 6 associate member registries of EUROCAT. METHODS Each registry description provides information on the history and funding of the registry, population coverage including any changes in coverage over time, sources for ascertaining cases of congenital anomalies, and upper age limit for registering cases of congenital anomalies. It also details the legal requirements relating to termination of pregnancy for fetal anomalies, the definition of stillbirths and fetal deaths, and the prenatal screening policy within the registry. Information on availability of exposure information and denominators is provided. The registry description describes how each registry conforms to the laws and guidelines regarding ethics, consent, and confidentiality issues within their own jurisdiction. Finally, information on electronic and web-based data capture, recent registry activities, and publications relating to congenital anomalies, along with the contact details of the registry leader, are provided. CONCLUSIONS The registry description gives a detailed account of the organizational and operational aspects of each registry and is an invaluable resource that aids interpretation and evaluation of registry prevalence data.


Molecular Psychiatry | 2016

X-exome sequencing of 405 unresolved families identifies seven novel intellectual disability genes

Hao Hu; Stefan A. Haas; Jamel Chelly; H. Van Esch; Martine Raynaud; A.P.M. de Brouwer; Stefanie Weinert; Guy Froyen; Suzanne Frints; Frédéric Laumonnier; Tomasz Zemojtel; Michael I. Love; Hugues Richard; Anne-Katrin Emde; Melanie Bienek; Corinna Jensen; Melanie Hambrock; Utz Fischer; C. Langnick; M. Feldkamp; Willemijn Wissink-Lindhout; Nicolas Lebrun; Laetitia Castelnau; J. Rucci; R. Montjean; Olivier Dorseuil; Pierre Billuart; Till Stuhlmann; Marie Shaw; Mark Corbett

X-linked intellectual disability (XLID) is a clinically and genetically heterogeneous disorder. During the past two decades in excess of 100 X-chromosome ID genes have been identified. Yet, a large number of families mapping to the X-chromosome remained unresolved suggesting that more XLID genes or loci are yet to be identified. Here, we have investigated 405 unresolved families with XLID. We employed massively parallel sequencing of all X-chromosome exons in the index males. The majority of these males were previously tested negative for copy number variations and for mutations in a subset of known XLID genes by Sanger sequencing. In total, 745 X-chromosomal genes were screened. After stringent filtering, a total of 1297 non-recurrent exonic variants remained for prioritization. Co-segregation analysis of potential clinically relevant changes revealed that 80 families (20%) carried pathogenic variants in established XLID genes. In 19 families, we detected likely causative protein truncating and missense variants in 7 novel and validated XLID genes (CLCN4, CNKSR2, FRMPD4, KLHL15, LAS1L, RLIM and USP27X) and potentially deleterious variants in 2 novel candidate XLID genes (CDK16 and TAF1). We show that the CLCN4 and CNKSR2 variants impair protein functions as indicated by electrophysiological studies and altered differentiation of cultured primary neurons from Clcn4−/− mice or after mRNA knock-down. The newly identified and candidate XLID proteins belong to pathways and networks with established roles in cognitive function and intellectual disability in particular. We suggest that systematic sequencing of all X-chromosomal genes in a cohort of patients with genetic evidence for X-chromosome locus involvement may resolve up to 58% of Fragile X-negative cases.


BMJ | 2015

Long term trends in prevalence of neural tube defects in Europe : population based study

Babak Khoshnood; Maria Loane; Hermien E. K. de Walle; Larraitz Arriola; Marie-Claude Addor; Ingeborg Barišić; Judit Béres; Fabrizio Bianchi; Carlos Matias Dias; Elizabeth S Draper; Ester Garne; Miriam Gatt; Martin Haeusler; Kari Klungsøyr; Anna Latos-Bielenska; Catherine Lynch; Bob McDonnell; Vera Nelen; Amanda J. Neville; Mary O'Mahony; Annette Queisser-Luft; Judith Rankin; Anke Rissmann; Annukka Ritvanen; Catherine Rounding; Antonín Šípek; David Tucker; Christine Verellen-Dumoulin; Diana Wellesley; Helen Dolk

Study question What are the long term trends in the total (live births, fetal deaths, and terminations of pregnancy for fetal anomaly) and live birth prevalence of neural tube defects (NTD) in Europe, where many countries have issued recommendations for folic acid supplementation but a policy for mandatory folic acid fortification of food does not exist? Methods This was a population based, observational study using data on 11 353 cases of NTD not associated with chromosomal anomalies, including 4162 cases of anencephaly and 5776 cases of spina bifida from 28 EUROCAT (European Surveillance of Congenital Anomalies) registries covering approximately 12.5 million births in 19 countries between 1991 and 2011. The main outcome measures were total and live birth prevalence of NTD, as well as anencephaly and spina bifida, with time trends analysed using random effects Poisson regression models to account for heterogeneities across registries and splines to model non-linear time trends. Summary answer and limitations Overall, the pooled total prevalence of NTD during the study period was 9.1 per 10 000 births. Prevalence of NTD fluctuated slightly but without an obvious downward trend, with the final estimate of the pooled total prevalence of NTD in 2011 similar to that in 1991. Estimates from Poisson models that took registry heterogeneities into account showed an annual increase of 4% (prevalence ratio 1.04, 95% confidence interval 1.01 to 1.07) in 1995-99 and a decrease of 3% per year in 1999-2003 (0.97, 0.95 to 0.99), with stable rates thereafter. The trend patterns for anencephaly and spina bifida were similar, but neither anomaly decreased substantially over time. The live birth prevalence of NTD generally decreased, especially for anencephaly. Registration problems or other data artefacts cannot be excluded as a partial explanation of the observed trends (or lack thereof) in the prevalence of NTD. What this study adds In the absence of mandatory fortification, the prevalence of NTD has not decreased in Europe despite longstanding recommendations aimed at promoting peri-conceptional folic acid supplementation and existence of voluntary folic acid fortification. Funding, competing interests, data sharing The study was funded by the European Public Health Commission, EUROCAT Joint Action 2011-2013. HD and ML received support from the European Commission DG Sanco during the conduct of this study. No additional data available.


Archives of Disease in Childhood | 2015

Epidemiology of congenital diaphragmatic hernia in Europe: a register-based study

Mark R. McGivern; Kate E. Best; Judith Rankin; Diana Wellesley; Ruth Greenlees; Marie-Claude Addor; Larraitz Arriola; Hermien E. K. de Walle; Ingeborg Barišić; Judit Béres; Fabrizio Bianchi; Elisa Calzolari; Bérénice Doray; Elizabeth S Draper; Ester Garne; Miriam Gatt; Martin Haeusler; Babak Khoshnood; Kari Klungsøyr; Anna Latos-Bielenska; Mary O'Mahony; Paula Braz; Bob McDonnell; Carmel Mullaney; Vera Nelen; Anette Queisser-Luft; Hanitra Randrianaivo; Anke Rissmann; Catherine Rounding; Antonín Šípek

Introduction Published prevalence rates of congenital diaphragmatic hernia (CDH) vary. This study aims to describe the epidemiology of CDH using data from high-quality, population-based registers belonging to the European Surveillance of Congenital Anomalies (EUROCAT). Methods Cases of CDH delivered between 1980 and 2009 notified to 31 EUROCAT registers formed the population-based case series. Prevalence over time was estimated using multilevel Poisson regression, and heterogeneity between registers was evaluated from the random component of the intercept. Results There were 3373 CDH cases reported among 12 155 491 registered births. Of 3131 singleton cases, 353 (10.4%) were associated with a chromosomal anomaly, genetic syndrome or microdeletion, 784 (28.2%) were associated with other major structural anomalies. The male to female ratio of CDH cases overall was 1:0.69. Total prevalence was 2.3 (95% CI 2.2 to 2.4) per 10 000 births and 1.6 (95% CI 1.6 to 1.7) for isolated CDH cases. There was a small but significant increase (relative risk (per year)=1.01, 95% credible interval 1.00–1.01; p=0.030) in the prevalence of total CDH over time but there was no significant increase for isolated cases (ie, CDH cases that did not occur with any other congenital anomaly). There was significant variation in total and isolated CDH prevalence between registers. The proportion of cases that survived to 1 week was 69.3% (1392 cases) for total CDH cases and 72.7% (1107) for isolated cases. Conclusions This large population-based study found an increase in total CDH prevalence over time. CDH prevalence also varied significantly according to geographical location. No significant association was found with maternal age.

Collaboration


Dive into the Anna Latos-Bielenska's collaboration.

Top Co-Authors

Avatar

Anna Materna-Kiryluk

Poznan University of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Miriam Gatt

Medical University of Graz

View shared research outputs
Top Co-Authors

Avatar

Aleksander Jamsheer

Poznan University of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Ester Garne

University of Southern Denmark

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mary O'Mahony

Health Service Executive

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Martin Haeusler

Medical University of Graz

View shared research outputs
Researchain Logo
Decentralizing Knowledge